Last checked at 21 Sep 2023 14:39
genedrive plc
("genedrive" or the "Company")
Application for Listing
Total Voting Rights
genedrive plc (AIM: GDR), the point of care molecular diagnostics company, confirms that in order to support the further drawdown and delivery of its £5M Equity Prepayment facility that was announced on 31 March 2023, application has been made for the Admission to trading on AIM of 3,100,000 new Ordinary Shares of 1.5p each ("New Ordinary Shares"). Admission of the New Ordinary Shares ("Admission") is expected to occur on 27 September 2023. Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.
Following Admission the Company's issued share capital will consist of 105,199,946 Ordinary Shares of 1.5p each and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
James Cheek: CEO / Russ Shaw: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Patrick Birkholm | |
Cavendish Capital Markets Ltd (Joint Broker) | +44 (0)20 7220 0500 |
Geoff Nash | |
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.